JnJ to discontinue Phase 3 VENTURA development program evaluating aticaprant for major depressive disorder
Titusville: Johnson & Johnson has announced the decision to discontinue the Phase 3 VENTURA development program evaluating aticaprant as an adjunctive treatment for major depressive disorder (aMDD) due to insufficient efficacy in the target patient population.
The data confirmed aticaprant is safe and well-tolerated, and no new safety signals were identified. Based on the potential for this mechanism, the Company will explore future development opportunities for aticaprant in other areas of high unmet need.
According to WHO, Depressive disorder (also known as depression) is a common mental disorder. It involves a depressed mood or loss of pleasure or interest in activities for long periods of time. Depression is different from regular mood changes and feelings about everyday life. It can affect all aspects of life, including relationships with family, friends and community. Depression can happen to anyone. People who have lived through abuse, severe losses or other stressful events are more likely to develop depression. Women are more likely to have depression than men.
An estimated 3.8% of the population experience depression, including 5% of adults (4% among men and 6% among women), and 5.7% of adults older than 60 years. Approximately 280 million people in the world have depression. Depression is about 50% more common among women than among men. Worldwide, more than 10% of pregnant women and women who have just given birth experience depression. More than 700 000 people die due to suicide every year. Suicide is the fourth leading cause of death in 15–29-year-olds.
Read also: Johnson & Johnson MedTech launches CEREGLIDE 92 Catheter System for Acute ischemic stroke
"Full analyses from the VENTURA development program are underway and will be shared at a future medical meeting," the release stated.
"Johnson & Johnson continues to build on its leadership in Neuroscience, as demonstrated by the Company’s significant investments in its current pipeline and the planned acquisition of Intra-Cellular Therapies, Inc. The Company remains focused on driving innovation in neuropsychiatric and neurodegenerative disorders," it added.
